Safety, Tolerability, and Pharmacokinetics of the β‐Site Amyloid Precursor Protein‐Cleaving Enzyme 1 Inhibitor Verubecestat (MK‐8931) in Healthy Elderly Male and Female Subjects

• Main Authors: Mark Forman (Author), John Palcza (Author), Jack Tseng (Author), Julie A. Stone (Author), Brittany Walker (Author), Dennis Swearingen (Author), Matthew D. Troyer (Author), Marissa F. Dockendorf (Author)
• Format: Book
• Published: Wiley, 2019-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

β‐site amyloid precursor protein‐cleaving enzyme 1 (BACE1) is required for the production of β‐amyloid peptides, which are implicated in the etiology of Alzheimer's disease. The safety and pharmacokinetics of the BACE1 inhibitor verubecestat have previously been studied in young adults aged 19-...